Introduction to Treating Patients with Buprenorphine for Primary Care Providers
12:00pm – 4:00pm
During May 2020–April 2021, the estimated number of drug overdose deaths in the United States exceeded 100,000 over a 12-month period for the first time. Medications for Opioid Use Disorder (MOUD), like Buprenorphine, methadone, and naltrexone have been proven to reduce overdose and death and providers that hold a DEA license with Schedule III Authority can prescribe Buprenorphine. Ensuring prescribers have the knowledge to initiate MOUD is imperative to helping patients with opioid use disorder. Q&A and discussion to follow.
BCBSM will provide a $250 incentive to Primary Care Physicians who attend this MOUD training. The incentive will be limited to the first 250 registered primary care physicians, so please register early to ensure a spot.
4 CME Credits Pending (4.0 hours)
Meets DEA Training Requirements
Understand the basics of the neurobiology of addiction
Understand the basic pharmacodynamics of buprenorphine
Describe the diagnosis, intake, buprenorphine induction of a patient with OUD.
Understand how to manage acute and chronic pain for patients with opioid use disorder with a specific emphasis on using buprenorphine for pain management
Describe key principles in outpatient management of patients with OUD
Sheba Sethi, MD
Eliza Hutchinson, MD
Who should take this training:
Primary Care Physicians